Search Results - "Chehrazi-Raffle, A."

Reply by Authors.

Authors: Gebrael G Sayegh N Tripathi N et al.

Source: Urology practice [Urol Pract] 2023 Oct 30, pp. 101097UPJ000000000000047102. Date of Electronic Publication: 2023 Oct 30.

Publication Type: Journal Article

Journal Info: Publisher: Wolters Kluwer Country of Publication: United States NLM ID: 101635343 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2352-0787 (Electronic) Linking ISSN: 23520779 NLM ISO Abbreviation: Urol Pract Subsets: MEDLINE

Integration of PSMA-Targeted Theranostics into Multidisciplinary Care for Improved Efficiencies and Patient Care.

Authors: Kuo, Phillip H. Poku, Erasmus Kofi Yamauchi, Dave M. et al.

Source: Journal of Nuclear Medicine Technology. Dec2025, Vol. 53 Issue 4, p300-304. 5p.

Disparities in Outcomes in Latino Subpopulations with Localized Prostate Cancer Undergoing Radical Prostatectomy: A Population-Based Analysis.

Authors: Jaime-Casas, Salvador Barragan-Carrillo, Regina Kothari, Anjaney et al.

Source: Cancers. Mar2026, Vol. 18 Issue 6, p1035. 14p.

Evaluating Worldwide Disparities in Bladder Cancer Clinical Trial Availability.

Authors: Shah, Koral U. Castro, Daniela V. Li, Xiaochen et al.

Source: Cancers. Jun2026, Vol. 18 Issue 11, p1730. 13p.

Eligibility Criteria in Advanced Urothelial Cancer Clinical Trials: An Assessment of Modernization and Inclusion.

Authors: Mercier, Benjamin D. Govindarajan, Ameish Castro, Daniela V. et al.

Source: Cancer Medicine. Apr2025, Vol. 14 Issue 7, p1-8. 8p.

Efficacy and safety of antibody-drug conjugate combination therapy in advanced urothelial carcinoma.

Authors: Jaime-Casas S Barragan-Carrillo R Zugman M et al.

Source: Frontiers in oncology [Front Oncol] 2025 Oct 07; Vol. 15, pp. 1669526. Date of Electronic Publication: 2025 Oct 07 (Print Publication: 2025).

Publication Type: Journal Article

Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE

Renal Cell Carcinoma: Review Article.

Authors: Samad, Khalid Mohamed Abdel Ragheb, Ahmed Sabry Seleem, Mohamed Mahmoud et al.

Source: Egyptian Journal of Hospital Medicine. Apr2026, Vol. 103 Issue 1, p1853-1859. 7p.

Cytokine-STAT3 Signaling Axis in Clear Cell Renal Cell Carcinoma: Implications for Tumor Microenvironment and Biomarker Discovery.

Authors: Šutovská, Martina Dohál, Matúš Gondáš, Eduard et al.

Source: Cancers. Jun2026, Vol. 18 Issue 12, p1972. 27p.

Clinical and Sociodemographic Determinants of Treatment Selection in Prostate Cancer: A Population-Based Study in the United States (2004–2022).

Authors: Pustake, Manas Railkar, Atharva Ongsyping, Stevenson et al.

Source: Cancers. Jun2026, Vol. 18 Issue 12, p1962. 11p.

Expression of PD-L1 and PD-L2 and Their Association with IFN-γ/STAT1/STAT3 Signaling in Human Clear Cell Renal Cell Carcinoma (ccRCC).

Authors: Kónya, Gábor Shammas, Ali Szabó, Erzsébet et al.

Source: Journal of Clinical Medicine. Jun2026, Vol. 15 Issue 11, p4384. 22p.

Clinical Predictors and Prognostic Significance of Pathologic Disease Upstaging at Radical Cystectomy in Patients with Muscle-Invasive Bladder Cancer.

Authors: Jaime-Casas, Salvador Yip, Wesley Lama, Daniel J. et al.

Source: Cancers. Oct2025, Vol. 17 Issue 19, p3265. 13p.

2025 INTERNATIONAL KIDNEY CANCER SYMPOSIUM: NORTH AMERICA.

Source: Journal of Kidney Cancer & VHL. 2026 Special Issue, Vol. 13, p1-65. 65p.

Assessment of eligibility criteria in renal cell carcinoma trials evaluating systemic therapy.

Authors: Castro, Daniela V. Prajapati, Sweta R. Feng, Matthew I. et al.

Source: BJU International. Mar2024, Vol. 133 Issue 3, p297-304. 8p.

Targeting STAT3 in tumor-associated antigen-presenting cells as a strategy for kidney and bladder cancer immunotherapy.

Authors: Alcantara MB Tang WS Wang D et al.

Source: Frontiers in immunology [Front Immunol] 2024 Jan 08; Vol. 14, pp. 1274781. Date of Electronic Publication: 2024 Jan 08 (Print Publication: 2023).

Publication Type: Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, N.I.H., Extramural

Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

This result is not displayed to guests.
Login for full access.

Assessment of Compliance With ASCO Language of Respect Guidelines in Renal Cell Carcinoma Abstracts.

Authors: Dizman N Agarwal R Castro DV et al.

Source: JCO oncology practice [JCO Oncol Pract] 2025 Nov; Vol. 21 (11), pp. 1689-1694. Date of Electronic Publication: 2025 Apr 07.

Publication Type: Journal Article

Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101758685 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2688-1535 (Electronic) Linking ISSN: 26881527 NLM ISO Abbreviation: JCO Oncol Pract Subsets: MEDLINE

Universal Antibody‐Engineered Lipid Nanoparticles Potentiate Chemo‐Immunotherapy Against Triple‐Negative Breast Cancer by Reprogramming Tumor Cell Metabolism.

Authors: Dai, Yeneng Wang, Jiaqi Liu, Yu et al.

Source: Advanced Science. 4/2/2026, Vol. 13 Issue 19, p1-15. 15p.

Evaluation of the Anticancer Effects of DODP on Gene Expression and Oxidative Stress in Gastric Cancer: An Integrated Docking, Bioinformatics, and Experimental Approach.

Authors: Agbektas, Tugba Coskun, Hakki Genc, Husnu Cagri et al.

Source: Life (2075-1729). Apr2026, Vol. 16 Issue 4, p534. 31p.

A Rare Case of TFE3‐Rearranged and SMARCB1‐Mutated Renal Cell Carcinoma: Diagnostic and Therapeutic Complexities.

Authors: Pecorin, Paul J. Dhliwayo, Nyembezi Christ, Trevor et al.

Source: Case Reports in Oncological Medicine. 2/24/2026, Vol. 2026, p1-5. 5p.

Risk Factors and Prediction Model for Early‐Onset Immune‐Related Adverse Events in Pan‐Cancer Patients Undergoing Anti‐PD‐(L)1 Therapy: A Retrospective Study in a Tertiary‐Level Hospital.

Authors: Jiao, Panpan Xue, Lijuan Tan, Weijuan et al.

Source: Cancer Medicine. Feb2026, Vol. 15 Issue 2, p1-11. 11p.